April 01, 2026

FDA Broadens CFTR Therapy Eligibility

The FDA expanded use of CFTR modulators to include more CF gene variants, increasing treatment eligibility across a wider US patient population.

Conexiant

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 30, 2026

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

Conexiant

March 27, 2026

FDA Drops Age Limit for Neffy

Needle-free epinephrine expands access for younger children meeting weight criteria

Conexiant

March 27, 2026

FDA Approves Gene Therapy for Severe Pediatric LAD-I

Approval expands treatment option for a rare pediatric immunodeficiency

Conexiant

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 23, 2026

Lyme Vaccine Advances in Late Trial

Large global study evaluates novel prevention strategy.

Conexiant

March 23, 2026

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) was approved today for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical ...

The ASCO Post

March 20, 2026

FDA Clears Setmelanotide for Hypothalamic Obesity

First and only FDA-approved therapy showed an 18.4% placebo-adjusted BMI reduction at 52 weeks

Conexiant

March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant